US2013022999A1PendingUtilityA1

Protein fragment complementation assays for the detection of biological or drug interactions

Assignee: ODYSSEY PHARMACEUTICALS INCPriority: Jan 31, 1997Filed: Jun 4, 2012Published: Jan 24, 2013
Est. expiryJan 31, 2017(expired)· nominal 20-yr term from priority
G01N 33/6803G01N 33/6845G01N 33/573C12N 15/1055G01N 33/542A01K 2267/0393G01N 33/5008A01K 67/0271Y02A90/10C07K 14/43595C07K 2319/00G01N 33/581A01K 2267/0331G01N 33/68G01N 33/58
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention describes a method for detecting biomolecular interactions said method comprising: (a) selecting an appropriate reporter molecule selected from the group consisting of a protein, a fluorescent protein, a luminescent protein and a phosphorescent protein; (b) effecting fragmentation of said reporter molecule such that said fragmentation results in reversible loss of reporter function; (c) fusing or attaching fragments of said reporter molecule separately to other molecules; followed by (d) reassociation of said reporter fragments through interactions of the molecules that are fused to said fragments; and (e) detecting said biomolecular interactions by reconstitution of activity of the reporter molecule

Claims

exact text as granted — not AI-modified
1 - 46 . (canceled) 
     
     
         47 . A method of testing the ability of a compound to inhibit molecular interactions in a PCA comprising performing a PCA in the presence of said compound and correlating any inhibition with said presence. 
     
     
         48 - 58 . (canceled) 
     
     
         59 . A host cell transfected with a nucleic acid composition coding for complementary fragments of a first molecule, each fused to separate molecules

Join the waitlist — get patent alerts

Track US2013022999A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.